Related Experiment Videos
[How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and
Abstract:
The possible chronotropic and arrhythmogenic effects of newly-developed oral inotropic agents were studied in 60 patients with idiopathic dilated cardiomyopathy (NYHA class II-IV). Changes in heart rates and the incidence of arrhythmias were evaluated using ambulatory electrocardiography. Denopamine 30 and 60 mg (beta 1 agonist), xamoterol 200 and 400 mg (beta 1 partial agonist) and OPC-8212 60, 90 and 120 mg (non-catecholamine) were sequentially administered for 10 +/- 2 months. Denopamine slightly increased heart rate throughout the day. Denopamine 60 mg caused excessive tachycardia in patients with atrial fibrillation, and could be used without digoxin. With xamoterol, maximum heart rate decreased during the daytime, while heart rate increased at night. Xamoterol was highly effective in patients with atrial fibrillation who not only had excessive tachycardia during exercise but marked bradycardia at night. Xamoterol increased the severity of heart failure in two patients who belonged to NYHA class IV, whose heart rates at rest had exceeded 100 beats/min. OPC-8212 did not affect heart rate, and was considered an ideal inotropic agent. None of these agents aggravated arrhythmias or caused sustained ventricular tachycardia. It was concluded that not only the severity of heart failure but the chronotropic and arrhythmogenic effects should be considered when choosing inotropic agents.
Insights
New oral inotropic agents were evaluated for heart rate and arrhythmia effects in dilated cardiomyopathy patients. OPC-8212 showed ideal inotropic effects without impacting heart rate, unlike denopamine and xamoterol.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Idiopathic dilated cardiomyopathy (IDCM) requires effective oral inotropic agents.
- Assessing chronotropic and arrhythmogenic effects is crucial for agent selection.
Purpose of the Study:
- To evaluate the chronotropic and arrhythmogenic effects of novel oral inotropic agents in IDCM patients.
- To compare denopamine, xamoterol, and OPC-8212 in terms of heart rate and arrhythmia changes.
Main Methods:
- 60 IDCM patients (NYHA class II-IV) received sequential oral denopamine, xamoterol, and OPC-8212.
- Ambulatory electrocardiography monitored heart rate and arrhythmias over 10 +/- 2 months.
Main Results:
- Denopamine slightly increased heart rate; 60 mg caused tachycardia in atrial fibrillation.
- Xamoterol altered heart rate patterns (daytime decrease, nighttime increase) and benefited some atrial fibrillation patients, but worsened heart failure in two NYHA class IV patients.
- OPC-8212 did not affect heart rate and was considered ideal.
- No agents aggravated arrhythmias or caused sustained ventricular tachycardia.
Conclusions:
- Inotropic agent selection for IDCM should consider heart failure severity, chronotropic, and arrhythmogenic effects.
- OPC-8212 presents as a promising inotropic agent due to its neutral effect on heart rate.